Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025

2025/08/14 by Susan L. Hills, Rebekah Sutter, Elaine R. Miller +8 · 1 voice · 1 citation
Medicine · Social Sciences · #Mosquito-borne diseases and control #Virology and Viral Diseases #Vaccine Coverage and Hesitancy

paper · pdf · doi:10.2807/1560-7917.es.2025.30.32.2500543

Abstract

A live attenuated chikungunya vaccine (IXCHIQ) received licensure in the United States (US) for ≥ 18-year-olds in November 2023. Post-licensure safety surveillance identified 28 adverse events in 2024 among US persons, including six neurological or cardiac serious adverse events (SAEs) in males ≥ 65 years. In early 2025, providers were alerted, a precaution for older persons was issued and vaccine guidance was updated. In May, following 11 additional SAEs reported outside the US, use in older persons was temporarily paused until 6 August 2025.

Cited by

• Fatal Adverse Event After VLA1553 Chikungunya Vaccination in an Elderly Patient: A Case Report From Reunion Island

Discussions

• 4/ In Feb 2025, the Vaccine Adverse Event Reporting System reported SAEs in 6 vaccinees over the age of 65 in the US in 2024 (doi.org/10.2807/1560...) [bsky, 7 points, 1 comments]

Related

• Fatal Adverse Event After VLA1553 Chikungunya Vaccination in an Elderly Patient: A Case Report From Reunion Island
• Effect of a Chikungunya Virus–Like Particle Vaccine on Safety and Tolerability Outcomes
• COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals
• Chikungunya resurgence highlights gaps in Aedes surveillance and control in South America
• Type I IFN autoantibodies underlie chikungunya live-attenuated vaccine encephalitis